What can Actavis contribute for the sustainability in the health care system?

0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% WEST EuUROPEEAST Number of patient treated by modern treatment according treatment guidelines GAP of unmeet needs Untreated patients or patients treated with “old” treatment

Europe: 48 % of all death (4.3 Million) EU-Europe (27 Member States): 42% (2 Mil) CHD – Europe: one of five 20% male - 22% female Stroke – Europe: one of six to one of ten 11% male – 17 % female CVD diseases mortality across Europe

Unequal distribution! Source: WHO 2004

CVD and DALY loss

Penetration of “Statins” Treatment Europe Treated patients Treated patients

Development of C10 Treatment in Czech Republic SIMVA for GP ATORVA for GP ROSUVA launch Source: IMS

Czech Market C10 Number of Treated vs. Price per Treatment IMS MAT 6/2011 Retail

Czech learning's Release of treatment of statins to GPs Rapid increase in number of patients treated by statins (10% of Czech population) 10 fold increase in number of treated patients 2 fold increase in yearly cost Shift of “standards’ “Extension of modern treatment to primary care”

Translation of Czech reality to Serbia 10% of Czech population treated In Serbia: ≈ patient to be considered Currently ≈ patients treated GAP patients

Meeting healthcare needs More affordable prices Modern therapies More patients treated Overall cost saving …in partnership with relevant authorities and through transparent dialogue! Actavis role in bringing sustainability to healthcare system

Thank you!